New Label Claim Acquired by Express® FP 10

New Label Claim Acquired by Express® FP 10

Prevention of urinary shedding of Leptospira borgpetersenii serovar hardjo (type hardjo-bovis) now available with one of the most complete modified-live virus/killed bacterin vaccines on the market.

Boehringer IngelheimEXPRESSBoehringer Ingelheim Vetmedica, Inc. enhances a vaccine that already stepped beyond conventional reproductive protection. Express® FP 10 currently provides one of the most complete modified-live virus/killed bacterin vaccine combinations on the market, and now it offers cross protection against Leptospira borgpetersenii serovar hardjo (type hardjo-bovis) (Lepto hardjo-bovis).

Lepto hardjo-bovis is associated with early embryonic deaths, poor conception rates, weak calves, as well as other reproductive losses in cattle. Express FP 10 offers five-way viral protection and protection against Lepto hardjo-bovis in just one syringe. Lepto hardjo-bovis is the primary hardjo that is isolated in the United States; all cattle herds are at risk for infection from it. In a recent study, challenged heifers vaccinated with Express FP vaccine were 100 percent protected against urinary shedding of Lepto hardjo-bovis, while all heifers in the unvaccinated control group were positive.1

“As demonstrated by new label claims and the guarantee Boehringer Ingelheim Vetmedica, Inc. puts behind this product, the introduction of Express FP 10 offers the dairy industry an effective vaccine for reproductive and respiratory protection in the dairy herd,” says Dr. Doug Ensley, Boehringer Ingelheim Vetmedica, Inc. Professional Services Veterinarian.

This product also includes new label claims for prevention of urinary shedding of Leptospira borgpetersenii serovar hardjo (type hardjo-bovis) and aids in prevention of key respiratory viruses. The expanded respiratory label adds to the reproductive protection for dairy and beef cattle for which Express FP products have long been known.

The Express FP line of reproductive vaccines offers dairy producers the original written guarantee that protects against financial loss should a BVD persistently infected calf be born from a properly vaccinated cow (See guarantee for details). It is reproductive and respiratory protection producers can count on.

“Express FP was the first modified-live viral vaccine to offer a written guarantee that calves born to a dam properly vaccinated with Express FP would be free of BVD persistent infection. This vaccine was created with your herd’s reproductive health in mind, protecting your animals against major reproductive diseases,” Ensley says. “The efficacy of Express FP vaccines has always been our top priority, and we will continue to offer that guarantee on our product.”

Read and follow all product label directions. For more information on Express FP, contact your veterinarian or Boehringer Ingelheim Vetmedica, Inc. representative.

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT, and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

For Boehringer Ingelheim — and its employees — carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.

In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24 percent of net sales in its largest business segment, Prescription Medicines, on research and development.

Boehringer IngelheimFor more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

For more information, please visit: www.bi-vetmedica.com.